High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture media

Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma

“…The gemcitabine molar incorporation index for the final synthetic covalent immunochemotherapeutic was determined by measuring difference in the moles of reduced sulfhydryl groups contained within thiolated anti-HER2/ neu fractions and gemcitabine-(carbamate)-[anti-HER2/neu] preparations applying 5,5 0 -dithiobis-(2-nitrobenzoic acid (DTNB) as a reagent for assaying reduced sulfhydryl groups (R-SH). 63,64 Quantitation of the amount of non-covalently bound gemcitabine contained within covalent gemcitabine-(carbamate)-[anti-HER2/ neu] preparations following separation by column chromatography was determined by measured absorbance at 265-267 nm 87,88 for the resulting supernatant after immunochemotherapeutic precipitation with methanol/acetonitrile (1:9 v/v).…”

Microemulsions for Intravesical Delivery of Gemcitabine

“…The 0.02 ml of clear supernatant was analyzed by HPLC method as reported previously with some modifications. 22) At the end of the intravesical administration experiment, the gemcitabine accumulation in the bladder was also determined by a homogenization method. After wash, the excised bladder cut to small pieces and place into a glass tube containing 2 ml saline in an ice bath.…”

Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer

“…The concentration of dFdCTP in PBMC cells was determined by HPLC (lowest sensitivity limit 0.25 mg/L) as described by Kirstein et al [10] and Huang et al [11] for chromatographic conditions and final sample preparation following deproteinization, respectively.…”